Cancer and Cancer Treatments on Cognitive Functions: At the Era of Comprehensive Mechanisms
Friday 8th, JULY 22, Paris, 9:00 AM – 6:15 PM
Call for abstracts : Abstract submission deadline: 3 June 2022, 23:59 CET
Organizers:
Hélène Castel (Univ Rouen, Inserm), Florence Joly (F. Baclesse Caen, Inserm), Bénédicte Giffard (Univ Caen, Inserm), Véronique Pancré (Cancéropôle Nord-Ouest, Lille)
Advances in diagnostic and therapeutic strategies in oncology have significantly increased the chance of survival of cancer patients, even those with metastatic disease. However, Cancer Related Cognitive Impairment (CRCI) is frequently reported in patients treated for non-central nervous system cancer, particularly during and after chemotherapy. These cognitive deficits, are characterized by impairment of short-term and working memory, attention, executive functions, and/or processing speed. First research have primarily focused on neuropsychological tests and clinical data with chemotherapy. Since then, a growing body of literature has highlighted the potential effects of cancer itself, and a new era is emerging on the role of other cancer treatments e.g., new modalities of radiotherapy, hormone therapies, targeted therapies, and immunotherapy on neurological functions, an important issue in terms of quality of life (QoL). Even now, it remains uncertain whether cognitive deficits result from the treatment, the cancer itself, and/or the psychological challenges of coping with cancer in the context of improved survival, or whether factors such as age, genetic polymorphisms, and psycho-social components or sleep disorders may predispose to a higher risk of cognitive impairment. To better understand the pathophysiology and neurobiological mechanisms of CRCI and the direct impact of the different cancer treatments, animal models have been developed to investigate selective and combined effects of the disease and treatment on neurocognitive function, the influence of parameters such as stress, mood and aging on cognitive impairment, while human brain imaging helped document mechanisms involved in CRCI. The growing demand for CRCI management from patients led to studies testing cognitive rehabilitation in cancer patients.
Call for abstracts
This meeting organized by the Cancéropôle Nord-Ouest and the French Plateform Cancer and Cognition, in collaboration with the University of Rouen Normandie deals with knowledge on translational research including clinical, imaging and animal models about CRCI. The objective is to bring together international specialists of the impact of cancer and treatments on brain function, addressing neuropsychological, neurobiological, and pathophysiological mechanisms, towards the search for predictive biomarkers and prevention tools.
Submit abstracts
Abstracts will be considered and included in the final scientific program after selection by the scientific committee, as oral communications (10 min) or flash communications (3 min).
Abstract submission deadline: June 3, 2022, 23:59 CET
Register and Submit an abstract :
https://www.escape.canceropole-nordouest.org/#/manifestation/subscription/46
Registration Fees: 70 euros
Abstract submission deadline: June 3, 2022, 23:59 CET
Deadline for registrations : June 15, 2022, 23:59 CET
Maximum 100 attendees
Satellite FENS Meeting Conference Theme
